-
12 far-reaching medical discoveries
Time of Update: 2021-10-21
Fleming, Flory and Chann won the Nobel Prize in Physiology or Medicine in 1945 for "the discovery of penicillin and its clinical effects .
-
In-depth analysis of Hengrui's innovative drug design cases, exploring the gold-digging road of "Yao Mao"
Time of Update: 2021-10-21
In another ATR inhibitor patent of Hengrui (CN 113135942 A), the best possible compound 3 is obtained from AZD-6738 backbone transition, isosteric, and ring closure.
-
The mission of gene therapy: the long march from rare disease drugs to mainstream drugs
Time of Update: 2021-10-20
direction and technical advantages and bottlenecks 4) Evaluation of safety and effectiveness 5 ) The industry's springing up and the blue sea and the red sea Speaker: Dr. Xiao Xiao, Chairman of Faith Pharmaceuticals Live time: October 19, 2021
-
Trax at the scene: the way of store execution management for medical and health companies
Time of Update: 2021-10-20
, the size of China's non-prescription drug market will continue to grow . >At the data level, the market size of China's over-the-counter drug industry has continued
-
The dual-channel target CDK7 R&D track is worthy of follow-up!
Time of Update: 2021-10-20
(see references for pictures) 02 CDK7 structural characteristics and mechanism of action On the structure, the crystal structure of CDK7-ATP complex has been determined, similar to the structure of CDK2-ATP complex, as shown in the figure below Show
-
? Patent analysis of small molecule drug design (WuXi AppTec ddsu article)
Time of Update: 2021-10-11
in the human non-small cell lung cancer NCI-H358 subcutaneous xenograft tumor model. Effective . At a dose of 3 mg/kg, 1-11A has a strong inhibitory effect on tumor growth, while increasing
-
Kinetisol? technology broadens the preparation space and analyzes its application in the preparation of pharmaceutical amorphous solid dispersions
Time of Update: 2021-10-11
tablets still have serious food effects and high variability. Patients need to take 1920 mg of the drug daily, which greatly reduces medication compliance. Verofenib prepared with Kinetisol technology- Hypromellose acetate succinate
-
Aceclofenac of non-steroidal anti-inflammatory drugs (NSAIDs)
Time of Update: 2021-10-10
Aceclofenac, as a non-steroidal anti-inflammatory drug (NSAID), has been approved to relieve pain and inflammation of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis .
-
Innovent announced the preliminary results of the Phase Ia dose escalation study of IBI315 (anti-Her2/PD-1 bispecific antibody) in patients with advanced solid tumors at the CSCO annual meeting in 2021
Time of Update: 2021-10-10
Professor Xichun Hu from the Cancer Hospital of Fudan University said: "IBI315 has shown good safety and preliminary effectiveness in the phase Ia study, and preliminary verification of the bispecific antibody design combining targeted therapy and immunotherapy .
-
How to write a clinical risk management plan for CAR-T cell therapy products that meets the registration requirements
Time of Update: 2021-10-10
[format] can be received free of charge (2) The new Drug Administration Law will be implemented on December 1, 2019. Approved by the drug regulatory department of the State Council, drug marketing license holders should develop a post-marketing
-
Medical companies join hands to carry out chip-level source innovation research
Time of Update: 2021-10-10
with medical high-tech companies to focus on major neurological disease research and brain science prospective research, and jointly build a brain science innovation center . > ><span
-
Who can change the pattern of atopic dermatitis treatment?
Time of Update: 2021-10-10
Two key phase III trials of Lebrikizumab, another IL-13 targeting antibody, ADvocate1 and ADvocate2, also reported reaching the 16-week EASI-75 primary endpoint.
-
Is the target CDK2 the highest stage clinical phase III worthy of further follow-up?
Time of Update: 2021-10-10
Among them, the targeted regulation of tumor cell cycle to change the apoptotic state of tumor cells has been clinically proven to be effective, and the specific representative species is the CDK family inhibitor .
-
How does "machine learning" help new drug development?
Time of Update: 2021-10-01
Machine learning (ML), as a branch of artificial intelligence, has multiple methods used in the drug discovery process to predict the molecular characteristics, biological activities, interactions, and adverse reactions of new chemical entities .
-
World Alzheimer's Day: How to improve the safety, compliance and accessibility of medicines?
Time of Update: 2021-10-01
of Alzheimer's disease medications Dosage form . Among them, transdermal patch is one of the important research directions . Compared with oral
-
Progress in clinical trials of drug treatment for dry eye in the past three years
Time of Update: 2021-09-30
Recently, Cornea magazine published the positive results of a phase 2b/3 clinical trial of CyclASol 0. 1%, a non-water drop eye solution of CyclASol, which was completed by Novaliq
-
Idiopathic pulmonary fibrosis (IPF) of rare diseases in China
Time of Update: 2021-09-30
1. Transforming growth factor β1 (TGF-β1) TGF-β family members include TGF-β1, TGF-β2 and TGF-β3, which are involved in inflammation, wound healing, extracellular matrix accumulation, bone formation, tissue development, cell differentiation and tumors progress and so on .
-
CSCO2021 Professor Li Jin: New hope for HER2-positive solid tumors, Phase I study of new ADC drug MRG002 announced
Time of Update: 2021-09-29
> . On the first day of the conference, the MRG002 phase I study led by Professor Li Jin from Dongji University Affiliated Hospital (Shanghai Dongfang Hospital) detonated anti-HER2 diagnosis and treatment hotspots
-
Sales of mythical new oral anticoagulant drugs
Time of Update: 2021-09-29
convert prothrombin into thrombin (thrombin), and thrombin converts fibrin into fibrin. The original enzymatically decomposes into fibrin monomers and cross-links to form a stable fibrin clot (fibrin), thereby completing the coagulation
-
Merck's $300 million anti-infective drug meets its rivals again!
Time of Update: 2021-09-20
Data source: CDE official website, Minet database A few days ago, the official website of CDE showed that Qilu Pharmaceutical (Hainan) was accepted for posaconazole injection with imitation of 4 types of applications .
